Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Ajman Government Media Office hosts Foreign Affairs Undersecretary at THE SIGNAL with a clear message: ‘The UAE does not seek the signal – it creates it’

    November 22, 2026

    Humaid bin Ammar attends day two of Ajman Media Forum 2026 and honours participants and partners

    November 22, 2026

    Ajman Government Media Office’s THE SIGNAL forum features Saeed Al Eter on how public trust and a successful development model underpin UAE soft power in times of crisis

    November 22, 2026
    • Automotive
    • Business
    • Entertainment
    • Health
    • Luxury
    • News
    • Lifestyle
    • Sports
    • Technology
    • Travel
    Arab DispatchArab Dispatch
    • Home
    • Contact Us
    Arab DispatchArab Dispatch
    Home » Pfizer signals growth in FY 2025 with revenue forecast of $64 billion
    Business

    Pfizer signals growth in FY 2025 with revenue forecast of $64 billion

    December 17, 2024
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    Pfizer Inc. (NYSE:PFE) has issued its financial guidance for the full year 2025, projecting revenue growth between $61 billion and $64 billion, representing a flat 5% operational increase from the midpoint of its 2024 guidance. The pharmaceutical giant also forecast adjusted diluted earnings per share (EPS) to rise between 10% and 18%, ranging from $2.80 to $3.00 per share, aligning closely with Wall Street expectations.

    Pfizer signals growth in FY 2025 with revenue forecast of $64 billion

    The company’s outlook factors in a $1 billion unfavorable impact from changes to Medicare Part D under the Inflation Reduction Act. Despite this, Pfizer stated it will continue implementing cost realignment strategies and manufacturing optimizations to achieve financial stability amid evolving market conditions.

    Pfizer’s projections come at a pivotal moment for the company, which has faced sharp declines in revenue following the pandemic-driven peak of its COVID-19 vaccine and treatment sales. The company expects 2025 sales for its COVID-19-related products to remain consistent with 2024 levels. Shares of Pfizer, which have dropped nearly 12% year-to-date, saw a modest rise of 2% in premarket trading following the guidance announcement.

    To strengthen its long-term growth prospects, Pfizer is focusing on advancing its drug pipeline, particularly in areas such as oncology and weight management. The company is currently conducting Phase 2 trials for danuglipron, an oral GLP-1 receptor agonist targeting weight loss. Early results have shown promise in reducing body weight, but the drug faces significant competition from established GLP-1 treatments such as Ozempic and Wegovy, which have gained widespread adoption.

    Pfizer’s leadership, under CEO Albert Bourla, has faced increasing scrutiny from investors, including activist hedge fund Starboard Value, which criticized the company’s acquisition strategy and its return on research and development investments. In response, Pfizer has prioritized cost management, debt reduction, and portfolio streamlining to rebuild investor confidence.

    Analysts remain cautiously optimistic about Pfizer’s pipeline, with JP Morgan analyst Chris Schott noting that while certain assets, particularly in oncology, appear promising, more significant progress will likely emerge beyond 2026. The near-term forecast reflects stability but highlights ongoing challenges in driving substantial revenue growth.

    As part of its Medicare-related adjustments, Pfizer acknowledged the additional financial pressures introduced by manufacturer discounts under the new legislation. The company anticipates these changes will offset expected benefits from the upcoming $2,000 cap on out-of-pocket expenses for seniors enrolled in Medicare Part D.

    Pfizer plans to provide further details on its financial outlook and strategic priorities during a scheduled conference call with analysts later today. Investors and stakeholders will closely monitor the company’s progress in navigating post-pandemic headwinds while advancing its pipeline to meet future growth expectations. – By EuroWire News Desk.

    Related Posts

    Chip boom lifts South Korea into $1 trillion export club

    November 21, 2026

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    Petrol price jump lifts South Africa inflation as SARB weighs rates

    November 18, 2026

    AfDB backs Morocco reforms and climate resilience with €434.4m

    November 14, 2026

    DP World partner ATI wins 25-year Manila port renewal

    November 13, 2026

    ADB flags $264 billion yearly ASEAN infrastructure gap

    November 12, 2026
    Editor's Pick

    Guinea declares mpox outbreak over after 42 days without cases

    November 21, 2026

    WFP seeks $12.1 billion to feed 91 million people in 2027

    November 21, 2026

    Chip boom lifts South Korea into $1 trillion export club

    November 21, 2026

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026
    © 2026 Arab Dispatch | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.